Omeros Corporation is a Seattle-based biopharmaceutical company focused on developing therapeutics for diseases with unmet medical needs, including biologics and small-molecule drugs.

# Company Summary: Omeros Corporation

**Overview:**
- Omeros Corporation is a biopharmaceutical company focused on developing and commercializing therapeutics, primarily targeting diseases with unmet medical needs. Their pipeline includes biologics and small-molecule drug candidates.

**Operations and Governance:**
- The company is headquartered at 201 Elliott Avenue West, Seattle, Washington 98119.
- It has 58,305,845 shares of common stock outstanding as of April 17, 2025.
- The company's securities are traded on The Nasdaq Stock Market LLC under the ticker symbol **OMER**.
- The company employs approximately 201 employees.

**Financial Highlights (as of the latest filing):**
- The **aggregate market value** of the voting and non-voting common stock held by non-affiliates was approximately **$224.8 million** as of the last business day of the second fiscal quarter of 2024.
- The **total revenue** and **net income** figures are not provided directly in the excerpt.

**Business Focus:**
- Omeros specializes in the discovery, development, and commercialization of drug therapies, with a focus on:
  - Inflammation
  - Immune-related disorders
  - Other serious conditions, including those related to the central nervous system and infectious diseases

**Corporate Development & Focus:**
- The company is at a stage where it is developing pipeline candidates aimed at addressing diseases like hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and IgA nephropathy.
- It maintains multiple clinical trial programs and has a diversified product pipeline.
- It has engaged in strategic financing and licensing agreements to support its development programs.

**Shareholder and Market Data:**
- The company's stock is closely held, with significant ownership by institutional investors like BlackRock, Inc., The Vanguard Group, and smaller holdings by directors, officers, and affiliates.
- The company has a dual focus on development-stage drug candidates and exploring commercialization opportunities.

**Regulatory & Reporting:**
- Filed a Form 10-K/A to amend its annual report for the fiscal year ending December 31, 2024, including detailed disclosures about corporate governance, executive compensation, and stock ownership.

---

**Note:** Specific figures for revenue, net income, or number of customers are not explicitly provided in the excerpt.

Omeros Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for immunologic diseases through innovative small-molecule and protein therapeutics.

# Omeros Corporation Overview

## Company Profile
- **Name:** Omeros Corporation
- **Type:** Clinical-stage biopharmaceutical company
- **Founded:** June 1994
- **Headquarters:** Seattle, Washington
- **Employees:** 198 full-time employees, with a workforce that includes 132 in research and development, 19 in sales and marketing, and 47 in finance, legal, business development, and administration.

## Business Focus
Omeros is dedicated to discovering, developing, and commercializing small-molecule and protein therapeutics primarily targeting immunologic diseases, including:
- **Complement-mediated diseases**
- **Cancer**
- **Addictive and compulsive disorders**

### Key Areas of Development
1. **Complement-Targeted Therapeutics:**
   - Focus on conditions associated with the complement system, a part of the immune system that can lead to various diseases when dysregulated.
   - **Current Programs:**
     - **Narsoplimab (OMS721):** 
       - Target: MASP-2, focusing primarily on hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
       - Status: Pivotal trial completed, working on BLA resubmission.
     - **OMS906:**
       - Target: MASP-3, focusing on conditions like paroxysmal nocturnal hemoglobinuria (PNH) and complement 3 glomerulopathy (C3G).
       - Status: Phase 2 clinical trials ongoing.
     - **OMS1029:** 
       - A long-acting, next-generation antibody targeting the lectin pathway.
       - Status: Phase 1 trial nearly complete.
2. **Other Development Programs:**
   - **OMS527:** 
     - A PDE7 inhibitor aimed at addiction and movement disorders, currently in Phase 1.
   - Immuno-oncology platforms, with five distinct preclinical programs targeting multiple cancer types.

### Financials
- **Revenue and Income:** 
  - For the year ended December 31, 2023, Omeros reported:
    - **Net Loss:** $117.8 million.
    - **Cash, Cash Equivalents, and Short-term Investments:** $171.8 million.
    - **Cash Provided by Operations:** $74.7 million.
- **Royalty Opportunities:**
  - Omeros has ongoing royalty agreements resulting from the sale of its previously marketed product, OMIDRIA, which includes potential future milestone payments based on sales performance.

### Customer Base
- Omeros initially marketed OMIDRIA to outpatient surgical facilities and hospitals in the U.S. The company's current customer base is focused on the healthcare providers and institutions involved in the treatment of specific immunological diseases.

## Long-Term Strategy
Omeros aims to:
- Advance its clinical programs to obtain regulatory approval for its drug candidates.
- Explore partnerships and collaborations to enhance its research capabilities and market reach.
- Explore the commercial landscape for therapeutics targeting both large market and orphan indications in immunologic diseases.

## Summary
Omeros Corporation focuses on the development of innovative therapies primarily aimed at complex diseases stemming from immune dysfunction. With multiple candidates currently in various stages of clinical trials, Omeros aims to address significant unmet medical needs while navigating the complexities of the biopharmaceutical landscape.

OMEROS CORP

10-K / April 30, 2025

10-K / April 1, 2024

10-K / April 30, 2025

Company Summary: Omeros Corporation